Ivor Kromholtz and Neri Azri represented Compugen, a dual-listed company traded on Nasdaq and the Tel Aviv Stock Exchange, in a transaction to monetize a portion of the future royalties to which it is entitled in respect of Rilvegostomig from the pharma giant AstraZeneca, in consideration for an amount of up to US$90 million. The transaction was carried out on a non-dilutive basis and improved Compugen’s financial position, while preserving significant potential future consideration for its benefit. Compugen is engaged in research and discovery of drugs and diagnostic products, and in collaborations for the development of the final products.
Click here to read the full article
